Research progress of myeloproliferative disorders: several clinical problems post the JAK2 mutation era

( views:, downloads: )
Author:
TIAN Ding(Department of Hematology, Xuanwu Hospital, Capital Medical University, Beijing 100053, China)
ZHU Ping()
SHEN Jian-liang()
WANG Zhao()
Journal Title:
JOURNAL OF LEUKEMIA & LYMPHOMA
Issue:
Volume 19, Issue 01, 2010
DOI:
10.3760/cma.j.issn.1009-9921.2010.01.002
Key Word:
Myeloproliferation disorders; Gene, JAK2; Mutation; Diagnosis; Therapy

Abstract: This critical review was summarized more systematically about the JAK2V617F mutation of related research progress in myeloproliferative disorders (MPD) research fields and the identification of JAK2V617F mutation represents an important advance in our understanding of MPD was agreed. The authors focused on several sensitive problems of post the JAK2 mutation era, and expressed their opinions. The Guideline of the MPD diagnostic criteria recommended by WHO in 2008 was accepted. The authors recommend the MPD, rather than myeloproliferative neoplasm (MPN). The treatment for the MPD (not including the CML) is recommended. Before the effective targeting of JAK2V617F specific inhibitors for the treatment of the MPD, short-term of use hydroxyurea (HU) was suggested to suppress excessive proliferation of bone marrow of MPD and a long course of treatment application of inteferon-α(IFN-α), and low-dose of aspirin in a timely manner were recommended to prevent thrombosis and other complications.

  • [1]James C,Ugo V,Le Couédic JP,et al.A unique clonal JAK2 mutation leading to constitutive.signaling causes polycythaemi a vera.Nature,2005,434:1144-1148.
  • [2]Baxter EJ,Scott LM,Campbell PJ,et al.Acquired mutation of the tyrosine kinase JAK2 in human myelopmliferative disorders.Lancet,2005,365:1054-1061.
  • [3]Levine RL,Wadleigh M,Cools J,et al.Activiting mutation in the tyrosine kinase JAK2 polycythaemia vera,essential thrombocythemia,and myeloid metaplasia with myelofibrosis.Cancer Cell,2005,7:387-397.
  • [4]Kralovics R,Passamonti F,Buser AS,et al.A gain-of-function mutation of JAK2 in myeloproliferative disorders.N Engl J Med,2005,352:1779-1790.
  • [5]Tefferi A.Classification,diagnosis and magagemant of myeloproliferative disorders in the JAK2617F era.Hematology Am Soc Hematol Educ Program,2006:240-245.
  • [6]Skoda R.The genec basis ofmyeloproliferative disorders.Hematology Am Soc Hematol Educ Program,2007:1-10.
  • [7]Prchal JT.Philadelphia chromosome-negativemyeloproliferative disorders:an historical perspective.Hematology Am Soc Hematol Educ Program,2008:68.
  • [8]James C.The JAK2V617F mutation in polycythemia vera and other myeloproliferative disorders:one mutatio for three Diseases? Hematology Am Soc Hematol Educ Program,2008:69-75.
  • [9]Levine RL,Wernig G.Role of JAK-STAT signnaling in the pathogenesis of myeloproliferative disorders.Hematology Am Soc Hematol Educ Program,2006:233-239.
  • [10]Verstovsek S.JAK2 inhibitor demonstrates effective,durable control of myelofibrosis.Hematology Am Soc Hematol Educ Program,2009:636-642.
  • [11]Jamieson CH,Gotlib J,Durocher JA,et al.The JAK2 V617F mutation occurs in hematopoietic stem cell in polycythemia vera and predisposes toward erythroid differentiation.Proc Natl Acad Sci U S A,2006,103:6224-6229.
  • [12]Scott LM,Tong W,Levine RL,et al.JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis.N Engl J Med,2007,356:459-468.
  • [13]Lucia E,Martino M,Gentile C,et al.The incidence of JAK2V617F mutation in bcr/abl-Negtive chronic myeloprolifirative disorders:assessment by two detection methods.Leuk Lymphoma,2008,49:1907-1915.
  • [14]刘红星,童春容,蔡鹏,等.多重位点特异性PCR检测骨髓增殖性疾病5种JAK2基因突变.中华检验医学杂志,2009,32:30-34.
  • [15]申徐良,陈方平,魏武,等.bcr-abl阴性骨髓增生性疾病患者JAK2 V617F点突变检测的临床意义.白血病·淋巴瘤,2008,17:119-122.
  • [16]张苏红,李伟达,宋君红,等.等位基因特异性聚合酶链反应结合测序对骨髓增殖性疾病JAK2V617F点突变的研究.中华医学杂志,2007,87:2109-2112.
  • [17]Xu XS,Zhang Q,Luo J,et al.JAK2V617F:prevalence in a large Chinese hospital population.Blood,2007,109:339-342.
  • [18]Tefferi A,Varidiman JW.Classification and diagnosis of myeloproliferative neoplasms:the 2008 World Health Organization criteria and point-of-care diagnostic algorithms.Leukemia,2008,22:14-22.
  • [19]Mesa RA.Navigating the evolving paradigms in the diagnosis and treatment of myeloproliferative disorders.Hematology Am Soc Hematol Educ Program,2007:355-362.
  • [20]Kerbauy DM,Gooley TA,Sale GE,et al.Hematopoietic cell transplantation as curative therapy for idiopathic myelofibrosis,advanced polycythemia vera,and essential thrombocythemia.Biol Blood Marrow Transplant,2007,13:355-365.
  • [21]张之南,沈悌.血液病诊断及疗效标准.3版.北京:科学出版社,2007:87-92,181-183.
  • [22]Vardiman JW,Harris NL,Brunning RD.The World Health Organization (WHO) classification of myeloid neoplasms.Blood,2002,100:2292-2302.
  • [23]Levine RL,Heaney M.New advances in the pathogeneses and therapy of essential thrombocythemia.Hematology Am Soc Hematol Educ Program,2008:76-82.
  • [24]Garber K.JAK2 inhibitors:not the next imatinib but researchers see other possibilities.J Natl Cancer Inst,2009,101:980-982.
  • [25]尹文杰,刘小鹏,宫立众.真性红细胞增多症转化为急性白血病并发结肠癌一例.白血病·淋巴瘤,2009,18:493.
WanfangData CO.,Ltd All Rights Reserved
About WanfangData | Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615 Email:yiyao@wanfangdata.com.cn